JP Morgan Chase’s Pacific Biosciences PACB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2019
Q4
Sell
-69,600
Closed -$359K 5807
2019
Q3
$359K Buy
+69,600
New +$389K ﹤0.01% 4332
2019
Q2
Sell
-2,000
Closed -$14K 5933
2019
Q1
$14K Sell
2,000
-239,200
-99% -$1.73M ﹤0.01% 5477
2018
Q4
$1.78M Buy
+241,200
New +$1.53M ﹤0.01% 3359
2016
Q2
Sell
-15,000
Closed -$128K 4910
2016
Q1
$128K Buy
+15,000
New +$148K ﹤0.01% 3703

Other funds holding PACB

JP Morgan Chase's PACB Position: Q1 2026 in Review

JP Morgan Chase reduced its Pacific Biosciences (PACB) stake by 70% in Q1 2026, selling an estimated $570K and leaving 138,504 shares worth $175K. The position accounts for ﹤0.01% of the portfolio, ranked #5541.

JP Morgan Chase first reported a position in PACB in Q2 2013 and has held it in 47 quarters since. The position peaked at $19.6M in Q1 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • JP Morgan Chase held 138,504 shares of Pacific Biosciences worth $175K as of Q1 2026.
  • JP Morgan Chase sold 318,404 Pacific Biosciences shares in Q1 2026, an estimated $570K.
  • Pacific Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #5541 holding.
  • JP Morgan Chase first reported a position in Pacific Biosciences in Q2 2013 and has held it in 47 quarters since.
  • JP Morgan Chase's Pacific Biosciences position peaked at $19.6M in Q1 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.